JP2022536412A5 - - Google Patents
Info
- Publication number
- JP2022536412A5 JP2022536412A5 JP2021573248A JP2021573248A JP2022536412A5 JP 2022536412 A5 JP2022536412 A5 JP 2022536412A5 JP 2021573248 A JP2021573248 A JP 2021573248A JP 2021573248 A JP2021573248 A JP 2021573248A JP 2022536412 A5 JP2022536412 A5 JP 2022536412A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- patient
- tumor
- gene expression
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861094P | 2019-06-13 | 2019-06-13 | |
| US62/861,094 | 2019-06-13 | ||
| PCT/US2020/037521 WO2020252331A1 (en) | 2019-06-13 | 2020-06-12 | Methods of treating cancer by targeting cold tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536412A JP2022536412A (ja) | 2022-08-16 |
| JP2022536412A5 true JP2022536412A5 (https=) | 2023-06-12 |
Family
ID=73781074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573248A Pending JP2022536412A (ja) | 2019-06-13 | 2020-06-12 | 「冷たい腫瘍」を標的とすることによるがんの治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12357633B2 (https=) |
| EP (1) | EP3983016A4 (https=) |
| JP (1) | JP2022536412A (https=) |
| KR (1) | KR20220024426A (https=) |
| CN (1) | CN115135324A (https=) |
| AU (1) | AU2020290508A1 (https=) |
| CA (1) | CA3143030A1 (https=) |
| IL (1) | IL288939A (https=) |
| MX (1) | MX2021015447A (https=) |
| WO (1) | WO2020252331A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4114398A1 (en) * | 2020-03-06 | 2023-01-11 | Celgene Quanticel Research, Inc. | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
| CN113421613B (zh) * | 2021-06-08 | 2024-06-18 | 吴安华 | 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法 |
| AU2024337882A1 (en) * | 2023-09-07 | 2026-02-19 | Sutter Bay Hospitals | Co-targeting ncoa3 and pd-1 for cancer therapy |
| CN117538544A (zh) * | 2023-11-22 | 2024-02-09 | 湛江中心人民医院 | 检测基因Ccdc181表达量的试剂在制备精子异常诊断产品中的应用 |
| KR20250143182A (ko) * | 2024-03-21 | 2025-10-01 | 차의과학대학교 산학협력단 | 시스플라틴에 대한 반응성의 예후를 나타내는 비소세포폐암 환자의 분류를 위한 분석방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160116474A1 (en) * | 2013-06-20 | 2016-04-28 | The Broad Institute, Inc. | Compositions and methods for detecting and treating glioblastoma |
| KR102400920B1 (ko) | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| LT3371152T (lt) * | 2015-11-05 | 2021-04-12 | Celgene Quanticel Research, Inc. | Kompozicijos, apimančios lizinui specifinės demetilazės-1 inhibitorių, turinčios pirimidino žiedą, ir jų panaudojimas vėžio gydymui |
| US11998540B2 (en) * | 2015-12-11 | 2024-06-04 | The General Hospital Corporation | Compositions and methods for treating drug-tolerant glioblastoma |
| ES2972741T3 (es) | 2016-08-10 | 2024-06-14 | Celgene Quanticel Res Inc | Tratamiento del carcinoma de células de Merkel |
| MA51507A (fr) * | 2016-12-09 | 2020-11-11 | Constellation Pharmaceuticals Inc | Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1 |
| WO2019083971A1 (en) * | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
-
2020
- 2020-06-12 MX MX2021015447A patent/MX2021015447A/es unknown
- 2020-06-12 WO PCT/US2020/037521 patent/WO2020252331A1/en not_active Ceased
- 2020-06-12 EP EP20822351.1A patent/EP3983016A4/en active Pending
- 2020-06-12 CN CN202080056280.1A patent/CN115135324A/zh active Pending
- 2020-06-12 US US17/618,415 patent/US12357633B2/en active Active
- 2020-06-12 JP JP2021573248A patent/JP2022536412A/ja active Pending
- 2020-06-12 CA CA3143030A patent/CA3143030A1/en active Pending
- 2020-06-12 AU AU2020290508A patent/AU2020290508A1/en not_active Abandoned
- 2020-06-12 KR KR1020227000323A patent/KR20220024426A/ko not_active Ceased
-
2021
- 2021-12-12 IL IL288939A patent/IL288939A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536412A5 (https=) | ||
| EP4232463B1 (en) | Interleukin-2-fc fusion proteins and methods of use | |
| US11865159B2 (en) | Therapeutic RNA | |
| JP7732977B2 (ja) | Ｈｐｖポリペプチドおよびｉｌ－２をコードするポックスウイルスと抗ｐｄ－ｌ１抗体の組合せ | |
| JP2022536412A (ja) | 「冷たい腫瘍」を標的とすることによるがんの治療方法 | |
| US20220185886A1 (en) | Methods for identifying biomarkers to predict treatment response | |
| WO2018136559A1 (en) | Methods for treating flaviviruses and zika infections | |
| JP2022513402A5 (https=) | ||
| IL272418B2 (en) | Abinotuzumab treatment of a new subgroup of DLBCL patients | |
| JP2023516745A5 (https=) | ||
| US20230089536A1 (en) | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc | |
| Calugareanu et al. | Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosus. | |
| RU2824962C1 (ru) | Комбинация поксвируса, кодирующего полипептиды вируса папилломы человека, и il-2 с антителом к pd-l1 | |
| Smith | Impact of Advanced Age and Dietary Energy Balance on Mammary Tumor Progression and the Tumor Microenvironment | |
| EA050900B1 (ru) | СЛИТЫЕ БЕЛКИ ИНТЕРЛЕЙКИН-2-Fc И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| HK40097253A (en) | Interleukin-2-fc fusion proteins and methods of use | |
| HK40097253B (en) | Interleukin-2-fc fusion proteins and methods of use |